Estrella ImmunopharmaESLA
13F holders, Q4 2024 (December 31)11holders +1
2new positions
1sold out
$1.17avg. 13F price*
At the end of Q4 2024, 11 institutions reported holding Estrella Immunopharma Inc. (ESLA) in their 13F filings, up 1 from Q3 2024. 2 opened new positions and 1 sold out. The largest holders were Geode Capital Management, LLC ($106K), UBS Group AG ($78K) and Atw Spac Management LLC ($48K).
- Company
- Estrella Immunopharma Inc.
- CUSIP
- 297584104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $38K |
| Exits | 1 | $17K |
All 13F filers, Q3 2024 → Q4 2024: 108,653 shares bought and 16,472 shares sold, net +92,181 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Geode Capital Management, LLC | 0.00% | Add +22.0% | 93,418 | $106K |
| UBS Group AG | 0.00% | Add +899.0% | 65,167 | $78K |
| Atw Spac Management LLC | 0.07% | No change | 40,000 | $48K |
| BlackRock, Inc. | 0.00% | Add +0.6% | 25,118 | $30K |
| State Street Corp. | 0.00% | New | 22,352 | $25K |
| Vanguard Group Inc. | 0.00% | No change | 21,684 | $25K |
| Two Sigma Securities, LLC | 0.00% | New | 10,640 | $13K |
| MASO CAPITAL PARTNERS Ltd | 0.02% | No change | 10,000 | $12K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -33.9% | 3,788 | $5K |
| Bank of America Corp. | 0.00% | No change | 83 | $100 |
| JPMorgan Chase & Co. | 0.00% | Reduce -3.7% | 26 | $29 |
"% of holder's portfolio" is ESLA's weight in each manager's 13F, not the share of Estrella Immunopharma Inc. the manager owns.